Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Share-based Compensation (2020 - 2025)

Journey Medical's Share-based Compensation history spans 6 years, with the latest figure at $1.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 28.81% year-over-year to $1.8 million, compared with a TTM value of $6.3 million through Dec 2025, up 3.12%, and an annual FY2025 reading of $6.3 million, up 3.12% over the prior year.
  • Share-based Compensation for Q4 2025 was $1.8 million at Journey Medical, down from $1.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $2.4 million in Q4 2021, with the low at $8000.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.3 million recorded in 2025.
  • Year-over-year, Share-based Compensation skyrocketed 17875.0% in 2022 and then crashed 63.26% in 2023.
  • Tracing DERM's Share-based Compensation over 5 years: stood at $2.4 million in 2021, then plummeted by 40.62% to $1.4 million in 2022, then crashed by 63.26% to $529000.0 in 2023, then skyrocketed by 160.49% to $1.4 million in 2024, then increased by 28.81% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Share-based Compensation are $1.8 million (Q4 2025), $1.9 million (Q3 2025), and $1.3 million (Q2 2025).